Moderna, Inc. Common Stock vs. Recursion Pharmaceuticals, Inc. Class A Common Stock
MRNA
Moderna, Inc. Common Stock
$172.94 +12.27%
VS RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock
$4.05 +2.02%
Moderna, Inc. Common Stock (MRNA) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| MRNA | RXRX | |
|---|---|---|
| Market Cap | $61.50 billion | $2.17 billion |
| Revenue (TTM) | $2.23 billion | $54.85 million |
| Net Income (TTM) | $-3,151,000,000 | $-518,884,000 |
MRNA leads on 2 of 3 size & scale factors.
Valuation
| MRNA | RXRX | |
|---|---|---|
| Price / Book | 9.10 | 2.37 |
| Price / Sales | 27.60 | 39.59 |
MRNA and RXRX split the valuation factors evenly.
Profitability
| MRNA | RXRX | |
|---|---|---|
| Net Margin | -141.43% | -945.92% |
| Return on Equity | -46.61% | -56.71% |
MRNA leads on 2 of 2 profitability factors.
Risk & Sentiment
| MRNA | RXRX | |
|---|---|---|
| Short Interest | 0.01% | 0.29% |
MRNA leads on 1 of 1 risk & sentiment factors.
Dig deeper: MRNA overview, MRNA financials, RXRX overview, RXRX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.